全球癌症生物療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計癌症生物療法市場將從 2025 年的 1,461.1 億美元成長到 2034 年的 2,402.3 億美元，2026 年至 2034 年的複合年成長率為 5.68%。

隨著全球癌症發生率的上升，全球癌症生物療法市場正在迅速擴張。生物療法，包括免疫療法、單株抗體和標靶治療，正成為重要的治療選擇。這些療法能夠幫助人體免疫系統更有效對抗癌症，其效果優於傳統化療。人們對先進癌症療法的認知不斷提高以及診斷技術的進步，正在推動這個市場的成長。

關鍵成長要素包括腫瘤學領域的持續研發、政府資助以及創新生物製藥臨床試驗的增加。製藥公司正大力投資開發副作用較少的標靶治療。此外，全球人口老化以及與文明病的癌症病例增加，也提高了對有效治療方法的需求。同時，個人化醫療的進步正在改善治療效果，並增強患者的信心。

未來，隨著新一代免疫療法和聯合療法的引入，市場預計將迎來強勁成長。開發中國家醫療基礎設施的持續改善將進一步擴大先進癌症治療的覆蓋範圍。隨著生物技術的進步和監管核准的加快，癌症生物療法市場有望在全球範圍內提供巨大的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球癌症生物療法市場：依治療方法類型分類

• 市場分析、洞察與預測
• 單株抗體
• 疫苗
• 細胞激素
• 基因治療

第5章 全球癌症生物療法市場：依癌症類型分類

• 市場分析、洞察與預測
• 乳癌
• 肺癌
• 結腸癌
• 攝護腺癌

第6章：全球癌症生物療法市場：依給藥途徑分類

• 市場分析、洞察與預測
• 靜脈注射
• 皮下注射
• 口服
• 肌肉內注射

第7章 全球癌症生物療法市場：以最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 癌症研究機構
• 製藥公司

第8章 全球癌症生物療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bristol-Myers Squibb
  • Sanofi
  • Eli Lilly
  • Regeneron Pharmaceuticals
  • Celgene
  • AbbVie
  • Gilead Sciences
  • Amgen
  • Intuitive Surgical
  • Johnson And Johnson
  • Pfizer
  • Merck
  • Roche
  • AstraZeneca
  • Novartis

The Cancer Biological Therapy Market size is expected to reach USD 240.23 Billion in 2034 from USD 146.11 Billion (2025) growing at a CAGR of 5.68% during 2026-2034.

The Global Cancer Biological Therapy Market is expanding rapidly due to the increasing prevalence of cancer worldwide. Biological therapies, including immunotherapy, monoclonal antibodies, and targeted therapies, are becoming key treatment options. These therapies help the body's immune system fight cancer more effectively compared to traditional chemotherapy. Rising awareness about advanced cancer treatments and improved diagnostic technologies are driving the growth of this market.

Key growth drivers include continuous research and development in oncology, government funding, and growing clinical trials for innovative biologic drugs. Pharmaceutical companies are investing heavily in developing targeted therapies with fewer side effects. The aging global population and lifestyle-related cancer cases are also increasing demand for effective treatment options. Additionally, advancements in personalized medicine are improving treatment outcomes and boosting patient confidence.

In the future, the market is expected to witness strong growth with the introduction of next-generation immunotherapies and combination treatment approaches. Expanding healthcare infrastructure in developing countries will further increase accessibility to advanced cancer treatments. As biotechnology continues to evolve and regulatory approvals become faster, the cancer biological therapy market is likely to offer significant growth opportunities worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Therapy

• Monoclonal Antibodies
• Vaccines
• Cytokines
• Gene Therapy

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

By Administration Route

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By End User

• Hospitals
• Cancer Research Institutes
• Pharmaceutical Companies

COMPANIES PROFILED

• BristolMyers Squibb, Sanofi, Eli Lilly, Regeneron Pharmaceuticals, Celgene, AbbVie, Gilead Sciences, Amgen, Intuitive Surgical, Johnson and Johnson, Pfizer, Merck, Roche, AstraZeneca, Novartis
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY TYPE OF THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Therapy
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cytokines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Administration Route
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type Of Therapy
  • 8.2.2 By Cancer Type
  • 8.2.3 By Administration Route
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type Of Therapy
  • 8.3.2 By Cancer Type
  • 8.3.3 By Administration Route
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type Of Therapy
  • 8.4.2 By Cancer Type
  • 8.4.3 By Administration Route
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type Of Therapy
  • 8.5.2 By Cancer Type
  • 8.5.3 By Administration Route
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type Of Therapy
  • 8.6.2 By Cancer Type
  • 8.6.3 By Administration Route
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CANCER BIOLOGICAL THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bristol-Myers Squibb
  • 10.2.2 Sanofi
  • 10.2.3 Eli Lilly
  • 10.2.4 Regeneron Pharmaceuticals
  • 10.2.5 Celgene
  • 10.2.6 AbbVie
  • 10.2.7 Gilead Sciences
  • 10.2.8 Amgen
  • 10.2.9 Intuitive Surgical
  • 10.2.10 Johnson And Johnson
  • 10.2.11 Pfizer
  • 10.2.12 Merck
  • 10.2.13 Roche
  • 10.2.14 AstraZeneca
  • 10.2.15 Novartis